Briefing Documents for Rescheduled Eteplirsen Ad Comm Released

The briefing documents for Sarepta’s Ad Comm on Monday, April 25th have been released. Like you, we will spend the next several days dissecting these documents so that we have a better idea of what to expect at Monday’s Ad Comm.

PPMD continues to work with Sarepta and our other Duchenne partners to make sure that next week’s Ad Comm on 4/25 will be as impactful as possible and ensure the decision we all want in this community: APPROVAL!

Click here to access the briefing documents.

Learn more

For more information about the FDA Ad Comms, please visit the links and resources that we at PPMD have compiled over the past few months with the assistance of our community members, regulatory advisors, and federal agency partners:

Views: 449


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2022   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service